StonvexLoading…
StonvexStonvexStonvexCore line items from ACLS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $839.05M | $1.02B | $1.13B | $920.00M |
Operating Income | $119.31M | $210.79M | $265.80M | $212.36M |
Net Income | $120.24M | $200.99M | $246.26M | $183.08M |
EPS (Diluted) | $3.80 | $6.15 | $7.43 | $5.46 |
Total Assets | $1.36B | $1.35B | $1.28B | $1.01B |
Total Liabilities | $326.67M | $335.99M | $417.08M | $346.38M |
Cash & Equivalents | $145.45M | $123.51M | $167.30M | $185.59M |
Free Cash Flow OCF − CapEx | $107.01M | $128.64M | $136.21M | $204.92M |
Shares Outstanding | 30.72M | 32.37M | 32.69M | 32.77M |